Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,071.70 +8.10 (+0.76%)
Streaming Delayed Price Updated: 2:52 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Earnings Outlook For Regeneron Pharmaceuticals
Via Benzinga
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
The company missed total sales and earnings expectations. 
Via Investor's Business Daily
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views
Via Benzinga
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) qualifies as a quality stock.
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
Could Regeneron Stock Help You Retire a Millionaire?
The blossoming biotech might give more than a nudge to investors in this project. 
Via The Motley Fool
Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. 
Via Benzinga
Exposures Product Safety
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. 
Via Benzinga
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package. 
Via InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. 
Via Benzinga
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
These businesses are on paths to extremely bright futures. 
Via The Motley Fool
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says. 
Via Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. 
Via Investor's Business Daily
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
Exposures Product Safety
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. 
Via Investor's Business Daily
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS) 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco. 
Via Investor's Business Daily
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
These innovative biotechs likely aren't done rewarding their shareholders. 
Via The Motley Fool
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
Wednesday, a court ruling that found Viatris Inc's (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.